NOVO NORDISK A S (NVO) Company Report

Novo Nordisk has entered into a licensing agreement with Omeros Corporation for the clinical-stage MASP-3 inhibitor, zaltenibart (formerly OMS906), gaining exclusive global rights for its development and commercialization.
The agreement includes an upfront payment of $240 million to Omeros and eligibility for up to $2.1 billion in total milestone payments and royalties.
Zaltenibart is a first-in-class humanized monoclonal antibody targeting MASP-3, which Novo Nordisk aims to position as a best-in-class treatment for rare blood and kidney disorders.

3 days ago

Morningstar

Novo Nordisk Seeks FDA Approval for Higher-Dose Wegovy

NVO

Product Launch

New Projects/Investments

Novo Nordisk has submitted a supplemental new drug application to the FDA for a higher 7.2 mg dose of its Wegovy obesity drug, seeking faster approval through the FDA’s Commissioner’s National Priority Voucher (CNPV) program.
Clinical trials showed that patients on the 7.2 mg dose achieved significantly greater weight loss, averaging 20.7% of their body weight over 72 weeks, compared to 17.5% with the standard 2.4 mg dose.
The CNPV program could lead to an FDA decision within one to two months.

Nov 26, 2025, 2:02 PM

WSJ

Novo Nordisk Reports Positive Phase 2 Trial Results for Amycretin in Type 2 Diabetes

NVO

New Projects/Investments

Novo Nordisk announced positive headline results from a phase 2 clinical trial for amycretin in people with type 2 diabetes, published on November 25, 2025.
The trial demonstrated that amycretin achieved statistically significant weight loss of up to 14.5% at 36 weeks and significant reductions in HbA1c, with up to 89.1% of participants reaching levels below 7%.
Both subcutaneous and oral formulations of amycretin appeared to have a safe and well-tolerated profile, consistent with other incretin and amylin-based therapies.
Based on these results, Novo Nordisk plans to initiate a phase 3 development programme for amycretin in adults with type 2 diabetes in 2026.

Nov 25, 2025, 1:19 PM

6-K

Novo Nordisk Reports Positive Phase II Results for Amycretin

NVO

New Projects/Investments

Product Launch

Novo Nordisk announced positive Phase II clinical trial results for amycretin, a next-generation drug targeting type 2 diabetes and obesity.
The trials demonstrated significant efficacy over 36 weeks, with weekly subcutaneous injections leading to up to 1.8% reductions in HbA1c and 14.5% weight loss, while daily oral doses resulted in up to 1.5% HbA1c reductions and 10.1% weight loss.
Novo Nordisk plans to advance amycretin into Phase III pivotal trials for diabetes next year, shifting its primary focus from obesity due to the positive data.
Following the announcement, Novo Nordisk's shares rose 4%.

Nov 25, 2025, 11:40 AM

Bloomberg

Novo Nordisk's Alzheimer's Drug Fails Late-Stage Trials

NVO

New Projects/Investments

Novo Nordisk's oral semaglutide, marketed as Rybelsus for type 2 diabetes, failed to slow cognitive decline in Alzheimer's patients during two late-stage clinical trials.
Following the announcement, Novo Nordisk's shares dropped significantly, with one report indicating a 10% decrease.
Due to the observed lack of efficacy, Novo Nordisk has decided to discontinue the planned one-year extension phase of the Alzheimer’s trials.
This outcome represents a setback for the company's aim to extend its successful GLP-1 medicine market into Alzheimer's treatment.

Nov 24, 2025, 11:33 AM

Bloomberg

Novo Nordisk's Semaglutide Alzheimer's Trials Fail to Meet Primary Endpoint

NVO

New Projects/Investments

Novo Nordisk announced that its oral semaglutide did not confirm superiority over placebo in reducing the progression of Alzheimer's disease in the evoke and evoke+ phase 3 trials.
While treatment with semaglutide resulted in improvement of Alzheimer’s disease-related biomarkers, this did not translate into a delay of disease progression.
Based on these efficacy results, the 1-year extension period in the evoke and evoke+ trials will be discontinued.

Nov 24, 2025, 11:21 AM

Press Release

Novo Nordisk Reduces Wegovy Prices and Prepares for Pill Launch

NVO

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Novo Nordisk has significantly reduced the cash price for most doses of its weight-loss drug Wegovy to $349, with introductory offers as low as $199 per month through March 2026.
This strategic pricing aims to expand U.S. market access, including for Medicare and Medicaid patients at a net price of $245 per month for injectable forms and $149 per month for starter doses.
The company plans an aggressive launch of a new pill form of Wegovy with sufficient supply, anticipating FDA approval by the end of the year.
While analysts expect reduced near-term sales and have lowered stock price targets for 2026, the company and analysts remain optimistic about stronger long-term growth beyond 2027 due to wider adoption.

Nov 17, 2025, 8:45 AM

CNBC

Novo Nordisk Elects New Board Members and Chair at EGM

NVO

Board Change

Proxy Vote Outcomes

Management Change

Novo Nordisk held an Extraordinary General Meeting on November 14, 2025, to elect new board members, with the proposals receiving more than 93% of the votes cast.
Lars Rebien Sørensen, Chair of the Novo Nordisk Foundation, was elected as the new Chair of the Board, intending to serve for two to three years maximum. Kester Young, Britt Meelby Jensen, and Steffen Engels were also elected as board members.
The company plans to add two to three new independent board members at the Annual General Shareholders Meeting in March 2026 to address the current imbalance of independent members on the board.
In 2024, Novo Nordisk's net sales increased by 129% to DKK 290 billion, operating profit rose 137% to DKK 228 billion, and R&D investments grew 211% to DKK 48 billion.

Nov 14, 2025, 1:00 PM

Transcript

Novo Nordisk Elects New Board Members and Outlines Governance Changes

NVO

Board Change

Layoffs

Proxy Vote Outcomes

Novo Nordisk held an Extraordinary General Meeting on November 14, 2025, to elect new board members, with Lars Rebien Sørensen appointed as the new Chair. The proposals for new board members received over 93% of the votes cast.
Lars Rebien Sørensen will temporarily serve as Chair of both Novo Nordisk and the Novo Nordisk Foundation for a maximum of two to three years, a deviation from the arm's length governance principle. The board plans to add two to three new independent board members by the March 2026 Annual General Meeting to improve balance.
The company reported strong 2024 financial performance, with net sales increasing 129% to DKK 290 billion, operating profit up 137% to DKK 228 billion, and R&D investments rising 211% to DKK 48 billion.
Novo Nordisk is implementing a company-wide transformation, which included staff cutbacks impacting 9,000 individuals, to simplify its organization and focus on growth opportunities in diabetes and obesity.

Nov 14, 2025, 1:00 PM

Transcript

Novo Nordisk Elects New Board Members and Discusses Governance

NVO

Board Change

Management Change

Layoffs

Proxy Vote Outcomes

An extraordinary general meeting was held on November 14, 2025, to elect new board members, including a new Chair and Vice Chair, following disagreements on governance principles and board composition between the outgoing board and the Novo Nordisk Foundation.
Lars Rebien Sørensen was elected as the new Chair, with Kester Young as Vice Chair, and Britt Meelby Jensen and Steffen Engels as new board members. Michael Dolsten withdrew his candidacy.
The new Chair, Lars Rebien Sørensen, will temporarily hold both the Chair positions of Novo Nordisk and the Novo Nordisk Foundation, a deviation from the arm's length principle, expected to last 2-3 years. The board plans to add two to three new independent board members at the Annual General Meeting in March 2026 to strengthen the board with pharma, OTC, and tech experience.
The outgoing board highlighted significant financial performance in 2024, with net sales increasing by 129% to DKK 290 billion and operating profit up by 137% to DKK 228 billion. R&D investments also increased by 211% to DKK 48 billion in 2024.
The company implemented staff cutbacks, impacting 9,000 individuals, to reallocate resources towards new skills and research projects.

Nov 14, 2025, 1:00 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for NOVO NORDISK A S.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What are NOVO NORDISK A S's strategic priorities?How is NOVO NORDISK A S positioned vs competitors?How did NOVO NORDISK A S do last quarter?

Let Fintool AI Agent track NOVO NORDISK A S's earnings for you

Get instant analysis when filings drop